$MGRX
MANGOCEUTICALS, INC. Stock $mgrx

$mgrx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224012508 Filed on April 01, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$163.2K	$244.4K	$731.5K
YoY Change	15.52%	2633.45%	8082.21%
Cost Of Revenue	$29.67K	$101.8K	$300.0K
YoY Change	15.92%	2388.75%	7234.72%
Gross Profit	$69.79K	$142.6K	$431.5K
YoY Change	-19.9%	2839.79%	8796.91%
Gross Profit Margin	42.77%	58.35%	58.99%
Selling, General & Admin	$2.238M	$2.711M	$9.650M
YoY Change	-5.92%	300.56%	383.38%
% of Gross Profit	3207.29%	1901.13%	2236.48%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$3.210K	$6.290K	$24.89K
YoY Change	-48.48%	62.95%	544.82%
% of Gross Profit	4.6%	4.41%	5.77%
Operating Expenses	$2.238M	$2.711M	$9.650M
YoY Change	-5.92%	300.57%	383.38%
Operating Profit	-$2.169M	-$2.568M	-$9.219M
YoY Change	-5.39%	282.24%	362.89%
Interest Expense	-$222.7K	-$6.470K
YoY Change	-2805.71%	259.44%
% of Operating Profit
Other Income/Expense, Net	-$222.7K	$6.470K	$6.470K
YoY Change	-2804.7%		-199.95%
Pretax Income	-$2.391M	-$2.568M	-$9.212M
YoY Change	4.7%	281.21%	361.07%
Income Tax
% Of Pretax Income
Net Earnings	-$2.391M	-$2.568M	-$9.212M
YoY Change	4.68%	281.21%	361.07%
Net Earnings / Revenue	-1465.39%	-1050.89%	-1259.4%
Basic Earnings Per Share	-$0.09		-$0.57
Diluted Earnings Per Share	-$0.09	-$0.13	-$0.57
COMMON SHARES
Basic Shares Outstanding	23.62M shares	17.04M shares	16.11M shares
Diluted Shares Outstanding	26.10M shares		16.11M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$490.2K	$739.0K	$739.0K
YoY Change	-83.37%	8.22%	8.22%
Cash & Equivalents	$490.2K	$739.0K	$739.0K
Short-Term Investments
Other Short-Term Assets	$13.30K	$60.95K	$60.95K
YoY Change	-74.79%	418.72%	418.72%
Inventory	$14.02K	$18.50K	$18.50K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$517.6K	$818.5K	$818.5K
YoY Change	-82.88%	17.83%	17.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.313K	$215.4K	$215.4K
YoY Change	-96.95%	83.31%	-26.17%
Goodwill
YoY Change
Intangibles	$14.61M	$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$16.94K	$16.94K	$16.94K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$14.72M	$232.3K	$232.3K
YoY Change	5295.73%	-24.73%	-24.73%
TOTAL ASSETS
Total Short-Term Assets	$517.6K	$818.5K	$818.5K
Total Long-Term Assets	$14.72M	$232.3K	$232.3K
Total Assets	$15.24M	$1.051M	$1.051M
YoY Change	362.23%	4.73%	4.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$718.7K	$140.8K	$140.8K
YoY Change	451.92%	317.96%	317.96%
Accrued Expenses	$72.12K	$70.31K	$70.31K
YoY Change	8.81%	18.29%	18.29%
Deferred Revenue
YoY Change
Short-Term Debt	$187.5K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.378M	$211.1K	$211.1K
YoY Change	601.47%	-19.0%	-19.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$30.12K	$64.96K	$64.96K
YoY Change	-69.07%	-49.52%	-49.52%
Total Long-Term Liabilities	$30.12K	$64.96K	$64.96K
YoY Change	-69.08%	-49.52%	-49.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.378M	$211.1K	$211.1K
Total Long-Term Liabilities	$30.12K	$64.96K	$64.96K
Total Liabilities	$1.408M	$276.0K	$276.0K
YoY Change	379.25%	-29.09%	-29.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$15.99M	-$11.23M
YoY Change	133.02%	457.02%
Common Stock	$2.913K	$2.142K
YoY Change	74.33%	60.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.83M	$774.8K	$774.8K
YoY Change
Total Liabilities & Shareholders Equity	$15.24M	$1.051M	$1.051M
YoY Change	362.23%	4.73%	4.73%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$2.391M	-$2.568M	-$9.212M
YoY Change	4.68%	281.21%	361.07%
Depreciation, Depletion And Amortization	$3.210K	$6.290K	$24.89K
YoY Change	-48.48%	62.95%	544.82%
Cash From Operating Activities	-$1.577M	-$1.698M	-$6.997M
YoY Change	-11.34%	161.37%	419.66%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$3.520K
YoY Change		-100.0%	-91.83%
Acquisitions
YoY Change
Other Investing Activities	$65.00K
YoY Change
Cash From Investing Activities	$65.00K	$0.00	-$3.520K
YoY Change		-100.0%	-91.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$7.225M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.988M	1.200M	7.057M
YoY Change	112.58%	140.24%	244.26%
NET CHANGE
Cash From Operating Activities	-1.577M	-1.698M	-6.997M
Cash From Investing Activities	65.00K	0.000	-3.520K
Cash From Financing Activities	1.988M	1.200M	7.057M
Net Change In Cash	476.0K	-497.8K	56.14K
YoY Change	-156.42%	161.11%	-91.5%
FREE CASH FLOW
Cash From Operating Activities	-$1.577M	-$1.698M	-$6.997M
Capital Expenditures		$0.00	$3.520K
Free Cash Flow		-$1.698M	-$7.001M
YoY Change		146.0%	403.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q4	us-gaap	Inventory Net InventoryNet		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty		usd
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense		usd
CY2022	MGRX	Investor Relations InvestorRelations		usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation		usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2023	MGRX	Imputed Interest Related Party ImputedInterestRelatedParty		usd
CY2023	us-gaap	Interest Expense InterestExpense		usd
CY2022	MGRX	Cash In Flow From Other Operating Activity CashInFlowFromOtherOperatingActivity		usd
CY2023	MGRX	Warrants For Service Cancelled WarrantsForServiceCancelled		usd
CY2023	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets		usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023	us-gaap	Interest Paid InterestPaid		usd
CY2022	us-gaap	Interest Paid InterestPaid		usd
CY2022Q4	us-gaap	Inventory Net InventoryNet		usd
CY2023Q4	us-gaap	Notes Payable NotesPayable		usd
CY2022Q4	us-gaap	Notes Payable NotesPayable		usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q4	MGRX	Lessee Operating Lease Liability Payments Due After Year Two LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	13431285	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23619500	shares
CY2023	dei	Auditor Firm AuditorFirmId	76
CY2023	dei	Auditor Name AuditorName	Turner, Stone & Company, L.L.P
CY2023	dei	Auditor Location AuditorLocation	Dallas, Texas
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	739006	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	682860	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	18501	usd
CY2023Q4	MGRX	Prepaid Expenses Related Party PrepaidExpensesRelatedParty	60953	usd
CY2022Q4	MGRX	Prepaid Expenses Related Party PrepaidExpensesRelatedParty	11745	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	818460	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	694605	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3863	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	96129	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	117499	usd
CY2023Q4	MGRX	Fixed Assets FixedAssets	96129	usd
CY2022Q4	MGRX	Fixed Assets FixedAssets	117499	usd
CY2023Q4	us-gaap	Deposits Assets DepositsAssets	16942	usd
CY2022Q4	us-gaap	Deposits Assets DepositsAssets	16942	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	119262	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	174241	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	136204	usd
CY2023Q4	us-gaap	Assets Assets	1050793	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	140765	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	63718	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	56725	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	211078	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	64961	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	64961	usd
CY2023Q4	us-gaap	Liabilities Liabilities	276039	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21419500	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21419500	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13365000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13365000	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2142	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1337	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12000785	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2628449	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11228173	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2015756	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1050793	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1003287	usd
CY2023	us-gaap	Revenues Revenues	731493	usd
CY2022	us-gaap	Revenues Revenues	8939	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	154900	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	4089	usd
CY2023	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	145092	usd
CY2023	us-gaap	Gross Profit GrossProfit	431501	usd
CY2022	us-gaap	Gross Profit GrossProfit	4850	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3319417	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1643572	usd
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	977890	usd
CY2023	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2097505	usd
CY2022	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	352860	usd
CY2023	MGRX	Investor Relations InvestorRelations	1100465	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2155114	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	9650391	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	1996432	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-9218890	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1991582	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	6473	usd
CY2022	MGRX	Imputed Interest Related Party ImputedInterestRelatedParty	-6473	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6473	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6473	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9212417	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1998055	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-9212417	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1998055	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16113029	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16113029	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10798083	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10798083	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-16720	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	540065	usd
CY2022	MGRX	Stock Issued During The Period Value Issuance Of Units For Cash StockIssuedDuringThePeriodValueIssuanceOfUnitsForCash	2000000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	234088	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	151821	usd
CY2022	MGRX	Adjustments To Additional Paid In Capital Stock Imputed Interest AdjustmentsToAdditionalPaidInCapitalStockImputedInterest	6473	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1998055	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	614030	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	614030	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1530651	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6200000	usd
CY2023	MGRX	Adjustments To Additional Paid In Capital Stock Imputed Interest Related Party Loan Repayment AdjustmentsToAdditionalPaidInCapitalStockImputedInterestRelatedPartyLoanRepayment	-6473	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	624463	usd
CY2023	MGRX	Stock Issued During The Period Value Warrant Exercised StockIssuedDuringThePeriodValueWarrantExercised	1024500	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-9212417	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	774754	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	774754	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-9212417	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1998055	usd
CY2023	us-gaap	Depreciation Depreciation	24889	usd
CY2022	us-gaap	Depreciation Depreciation	3863	usd
CY2023	MGRX	Issuance Of Common Stock For Services IssuanceOfCommonStockForServices	1530651	usd
CY2022	MGRX	Issuance Of Common Stock For Services IssuanceOfCommonStockForServices	540065	usd
CY2022	us-gaap	Interest Expense InterestExpense	6473	usd
CY2023	MGRX	Cash In Flow From Other Operating Activity CashInFlowFromOtherOperatingActivity	-6473	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	624463	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	234088	usd
CY2022	MGRX	Warrants For Service Cancelled WarrantsForServiceCancelled	-151821	usd
CY2022	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	16942	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	18501	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	49208	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	11745	usd
CY2023	MGRX	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-54979	usd
CY2022	MGRX	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	174241	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	107090	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	33675	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-56726	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	185405	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	3878	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	2717	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6997375	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1346518	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3519	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	43102	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3519	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-43102	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	75000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	78260	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	89200	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	25070	usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1024500	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6200000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7057040	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2049930	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	56146	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	660310	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	682860	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22550	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	739006	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	682860	usd
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zTaBj30XFrTh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zamGauzDKjhd">Use of Estimates and Assumptions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results can, and in many cases will, differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zYXIXKxlUq6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zDtTJX7Zm2Ol">Concentration and Risks</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s operations are subject to risks including financial, operational, regulatory and other risks including the potential risk of business failure. For the years ended December 31, 2023 and 2022, the Company had no significant revenue from continuing operations which were derived from a single or a few major customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2097505	usd
CY2022	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	352860	usd
CY2023Q4	MGRX	Prepaid Expenses Related Party PrepaidExpensesRelatedParty	60953	usd
CY2022Q4	MGRX	Prepaid Expenses Related Party PrepaidExpensesRelatedParty	11745	usd
CY2022Q4	us-gaap	Deposits Deposits	16942	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	18501	usd
CY2023	us-gaap	Depreciation Depreciation	24889	usd
CY2022	us-gaap	Depreciation Depreciation	3863	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	96129	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	117499	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	28752	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3863	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	96129	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	117499	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	78260	usd
CY2023Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	5000	usd
CY2023Q2	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	31630	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	63260	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21419500	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21419500	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13365000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13365000	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	624463	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	82267	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1250000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.10
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1250000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.10
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	133333	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.10
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1250000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.10
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1400000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.40
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2650000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.73
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1812500	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.73
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	573202	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	31995	usd
CY2023Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	271216	usd
CY2023	MGRX	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue	1.43
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-9212417	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11228173	usd
CY2022Q3	us-gaap	Area Of Land AreaOfLand	2201	sqft
CY2022Q3	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Lease Agreement has a term of thirty-eight (38) months and has a monthly base rent of $5,777.63, or $31.50 per square foot, the from months 3-18 and increases at the rate of $1 per square foot per annum until the end of the lease term
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P38M
CY2022Q3	us-gaap	Payments For Rent PaymentsForRent	5777.63	usd
CY2022Q3	MGRX	Percentage Of Proportionate Rent PercentageOfProportionateRent	0.0245	pure
CY2022Q3	MGRX	Percentage Of Incremental Borrowing Rate PercentageOfIncrementalBorrowingRate	0.08	pure
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	119262	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	128679	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	65274	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	71716	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	67589	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	139305	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10626	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	128679	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9212417	usd
CY2023Q4	MGRX	Decrease In Deferred Tax Assets Valuation Allowance DecreaseInDeferredTaxAssetsValuationAllowance	9212417	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	11228173	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11228173	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2015756	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11228173	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2015756	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-012508-index-headers.html	Edgar Link	pending
0001493152-24-012508-index.html	Edgar Link	pending
0001493152-24-012508.txt	Edgar Link	pending
0001493152-24-012508-xbrl.zip	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-1_001.jpg	Edgar Link	pending
ex3-3.htm	Edgar Link	pending
ex3-3_001.jpg	Edgar Link	pending
ex3-3_002.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-5.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_003.jpg	Edgar Link	pending
form10-k_005.jpg	Edgar Link	pending
form10-k_006.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mgrx-20231231.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mgrx-20231231_cal.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
mgrx-20231231_lab.xml	Edgar Link	unprocessable
mgrx-20231231_pre.xml	Edgar Link	unprocessable
mgrx-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MGRX
MANGOCEUTICALS, INC. Stock $mgrx

2024 Q2 Form 10-K Financial Statement

#000149315224012508 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGRX MANGOCEUTICALS, INC. Stock $mgrx

2024 Q2 Form 10-K Financial Statement

#000149315224012508 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGRX
MANGOCEUTICALS, INC. Stock $mgrx